S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

PaxMedica (PXMD) Stock Price, News & Analysis

$0.69
-0.07 (-9.16%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.68
$0.76
50-Day Range
$0.69
$5.53
52-Week Range
$0.68
$69.19
Volume
484,265 shs
Average Volume
3.64 million shs
Market Capitalization
$1.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

PaxMedica MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
332.3% Upside
$3.00 Price Target
Short Interest
Bearish
14.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of PaxMedica in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$6,570 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.35) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars


PXMD stock logo

About PaxMedica Stock (NASDAQ:PXMD)

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

PXMD Stock Price History

PXMD Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
PaxMedica (NASDAQ:PXMD) Now Covered by HC Wainwright
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
PaxMedica Announces Pricing of $7M Public Offering
Why Is PaxMedica (PXMD) Stock Up 57% Today?
Why Is PaxMedica (PXMD) Stock Down 40% Today?
Crude Oil Gains Over 2%; PaxMedica Shares Plunge
What's Going On With PaxMedica Stock Today?
PaxMedica CMO Featured in Latest Bell2Bell Podcast Release
See More Headlines
Receive PXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PXMD
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+332.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.15 per share

Miscellaneous

Free Float
965,000
Market Cap
$1.59 million
Optionable
Not Optionable
Beta
0.28
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














PXMD Stock Analysis - Frequently Asked Questions

Should I buy or sell PaxMedica stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PaxMedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PXMD shares.
View PXMD analyst ratings
or view top-rated stocks.

What is PaxMedica's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for PaxMedica's shares. Their PXMD share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 332.3% from the stock's current price.
View analysts price targets for PXMD
or view top-rated stocks among Wall Street analysts.

How have PXMD shares performed in 2023?

PaxMedica's stock was trading at $34.51 on January 1st, 2023. Since then, PXMD shares have decreased by 98.0% and is now trading at $0.6940.
View the best growth stocks for 2023 here
.

Are investors shorting PaxMedica?

PaxMedica saw a increase in short interest in November. As of November 15th, there was short interest totaling 327,500 shares, an increase of 651.1% from the October 31st total of 43,600 shares. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is presently 0.2 days.
View PaxMedica's Short Interest
.

When is PaxMedica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our PXMD earnings forecast
.

How were PaxMedica's earnings last quarter?

PaxMedica, Inc. (NASDAQ:PXMD) posted its quarterly earnings data on Wednesday, November, 15th. The company reported ($5.20) EPS for the quarter.

When did PaxMedica's stock split?

PaxMedica shares reverse split on the morning of Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did PaxMedica IPO?

(PXMD) raised $9 million in an initial public offering on Friday, August 26th 2022. The company issued 1,600,000 shares at a price of $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO.

How do I buy shares of PaxMedica?

Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PXMD) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -